What is the effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease?
According to the study conducted by Edwards et al. (2009), the use of spironolactone is associated with a reduction in left ventricular mass and aortic stiffness in early-stage chronic kidney disease. The study showed that patients who received spironolactone had significantly lower left ventricular mass index and aortic stiffness compared to the control group. Furthermore, the results indicated that spironolactone had a beneficial effect on parameters of systolic and diastolic function, indicating that it may be effective in slowing the progression of chronic kidney disease.